Modeling acute graft-versus-host disease (aGVHD) in murine bone marrow transplantation (BMT) models with MHC disparity.
Scheurer J, Leithäuser F, Debatin KM, Strauss G.
Methods Cell Biol. 2022;168:19-39. doi: 10.1016/bs.mcb.2021.12.007. Epub 2022 Jan 10.
Treatment of acute and chronic graft-versus-host disease with extracorporeal photopheresis: Update of best practice recommendations from Italian Society of Hemapheresis and Cell Manipulation (SIdEM) and the Italian Transplant Group for Bone Marrow Transplantation, Hematopoietic Stem Cells and Cell Therapy (GITMO).
Colpo A, Marchetti M, Bianco I, Cruciani F, Ipsevich F, Montanari M, Stanghellini MTL; Italian Society of Hemapheresis and Cell Manipulation (SIdEM) and the Italian Transplant Group for Bone Marrow Transplantation, Hematopoietic Stem Cells and Cell Therapy (GITMO).
Transfus Apher Sci. 2024 Oct;63(5):103990. doi: 10.1016/j.transci.2024.103990. Epub 2024 Aug 13.
Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults.
Kiene S, Albrecht M, Theurich S, Scheid C, Skoetz N, Holtick U.
Cochrane Database Syst Rev. 2024 Nov 7;11(11):CD010189. doi: 10.1002/14651858.CD010189.pub3.
Evaluation of Immunosuppression Levels and Risk of Graft-Versus-Host Disease in Allogeneic Blood or Marrow Transplantation With Post-Transplantation Cyclophosphamide.
Lee JJ, Norman H, Ziggas JE, Bolaños-Meade J, Porter TJ.
Transplant Cell Ther. 2025 Jun;31(6):363.e1-363.e11. doi: 10.1016/j.jtct.2025.02.024. Epub 2025 Mar 3.
Hepatobiliary disease after bone marrow transplant.
Dezan MGF, Cavalcante LN, Cotrim HP, Lyra AC.
Expert Rev Gastroenterol Hepatol. 2023 Feb;17(2):129-143. doi: 10.1080/17474124.2023.2169671. Epub 2023 Feb 2.
Influence of tumor vaccines on graft versus tumor activity and graft versus host disease in allogeneic bone marrow transplantation.
Mullen CA.
Leuk Lymphoma. 2002 Mar;43(3):503-10. doi: 10.1080/10428190290011976.
Development of Grade II Acute Graft-versus-Host Disease Is Associated with Improved Survival after Myeloablative HLA-Matched Bone Marrow Transplantation using Single-Agent Post-Transplant Cyclophosphamide.
McCurdy SR, Kanakry CG, Tsai HL, Gojo I, Smith BD, Gladstone DE, Bolaños-Meade J, Borrello I, Matsui WH, Swinnen LJ, Huff CA, Brodsky RA, Ambinder RF, Fuchs EJ, Rosner GL, Jones RJ, Luznik L.
Biol Blood Marrow Transplant. 2019 Jun;25(6):1128-1135. doi: 10.1016/j.bbmt.2018.12.767. Epub 2018 Dec 30.
Ambivalent role of FasL in murine acute graft-versus-host-disease.
Bernard-Bloch R, Lebrault E, Li X, Sutra Del Galy A, Garcia A, Doliger C, Parietti V, Legembre P, Socié G, Karray S.
J Leukoc Biol. 2023 Sep 1;114(3):205-211. doi: 10.1093/jleuko/qiad040.
Allogeneic blood or marrow transplantation using haploidentical grandchildren donors and post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis.
Aljawai YM, Tsai HL, Varadhan R, Jones RJ, Imus PH.
Br J Haematol. 2024 Oct;205(4):1469-1476. doi: 10.1111/bjh.19673. Epub 2024 Aug 4.
Haploidentical bone marrow and stem cell transplantation: experience with post-transplantation cyclophosphamide.
Robinson TM, O'Donnell PV, Fuchs EJ, Luznik L.
Semin Hematol. 2016 Apr;53(2):90-7. doi: 10.1053/j.seminhematol.2016.01.005. Epub 2016 Jan 15.
